2. Signaling Pathways
  3. Neuronal Signaling
  4. Tau Protein
  5. Tau Protein Inhibitor

Tau Protein Inhibitor

Tau Protein Inhibitors (46):

Cat. No. Product Name Effect Purity
  • HY-169196
    D-687
    		Inhibitor
    D-687 is an inhibitor of Tau and Aβ. D-687 can reverse Aβ1–42-induced toxicity in SH-SH5Y cells and has significant neuroprotective properties.
  • HY-149237
    hAChE-IN-2
    		Inhibitor
    hAChE-IN-2 is a potent hAChE inhibitor, with an IC50 of 0.71 μM. hAChE-IN-2 can also inhibits tau-oligomerization, with an EC50 of 2.21 μM. hAChE-IN-2 exhibits neuroprotective activity.
  • HY-172176
    RA-PR058
    		Inhibitor
    RA-PR058 is an orally active Ramalin derivative with blood-brain barrier permeability, exhibiting multi-target regulatory effects and favorable pharmacokinetic properties. RA-PR058 demonstrates potential as a multi-target modulator for Alzheimer's disease by reducing the expression of BACE1, tau protein hyperphosphorylation, and anxiety-like behaviors.
  • HY-162812
    H3R antagonist 4
    		Inhibitor
    H3R antagonist 4 (compound 11L) was a dual inhibitor of cholinesterase and histamine receptor (H3R), with corresponding IC50 of 7.04 μM (eeAChE), 9.73 μM (hAChE)(reversible) and 1.09 nM (H3R) , respectively. H3R antagonist 4 inhibited the aggregation of Aβ1-42 induced by itself and Cu2+ (95.48% and 88.63%) , and degraded the Aβ1-42 fibrils induced by itself and Cu2+ (80.16% and 89.30%) . H3R antagonist 4 chelate biometals such as Cu2+, Zn2+, Al3+, and Fe2+. H3R antagonist 4 significantly reduced tau protein hyperphosphorylation induced by Aβ1-42 and inhibited RSL-3-induced apoptosis and ferroptosis in PC12 cells. H3R antagonist 4 had the best blood-brain barrier permeability and intestinal absorption in hCMEC/D3 and hPepT1-MDCK cells.H3R antagonist 4 ameliorates learning and memory impairment in a mouse model of Alzheimer's disease induced by scopolamine (HY-N0296) .
  • HY-169197
    D-688
    		Inhibitor
    D-688 is an inhibitor of Tau and Aβ. D-688 can reverse Aβ1–42-induced toxicity in SH-SH5Y cells and has significant neuroprotective properties. D-688 can improve the survival rate of Drosophila melanogaster expressing the human tau protein isoform (2N4R).
  • HY-168079
    GSK-3β inhibitor 21
    		Inhibitor
    GSK-3β inhibitor 21 (compound 44) is an ATP-competitive GSK-3β inhibitor (IC50=6.06 μM) with anti-amyloid aggregation and tau phosphorylation inhibitory activities. GSK-3β inhibitor 21 can be used in the study of Alzheimer's disease.
  • HY-162750
    ZJCK-6-46
    		Inhibitor
    ZJCK-6-46 (32) is a potential and orally activeDYRK1A inhibitor (IC50 = 0.68 nM) with high BBB permeability (CNS+). ZJCK-6-46 (32) reduces tau phosphorylation. ZJCK-6-46 (32) ameliorates cognitive dysfunction by obviously reducing the expression of phosphorylated tau and neuronal loss in vivo.
  • HY-159898
    AChE/BChE-IN-23
    		Inhibitor
    AChE/BChE-IN-23 (Compound 6e) is an AChE/BChE inhibitor (IC50: 0.91 μM, 1.19 μM and 1.01 μM for hAChE, eq BChE and hBChE, respectively). AChE/BChE-IN-23 has antioxidant activity and inhibits Aβ1-42 and Tau protein aggregation. AChE/BChE-IN-23 also inhibits microglial activation by reducing ROS release and mitochondrial injury. AChE/BChE-IN-23 suppresses NLRP3 inflammasome and pro-inflammatory cytokines in human microglial cells. AChE/BChE-IN-23 also reverses the Scopolamine (HY-N0296)-induced memory impairment in mice model.
  • HY-149272
    tau/Aβ40 aggregation-IN-1
    		Inhibitor
    tau/Aβ40 aggregation-IN-1 (Compound 20) is a tau and Aβ40 aggregation inhibitor with IC50s of 1.8 μM and 1.3 μM, respectively.
  • HY-149542
    GSK-3β inhibitor 15
    		Inhibitor
    GSK-3β inhibitor 15 (Compound 54) is a GSK-3β inhibitor (IC50: 3.4 nM). GSK-3β inhibitor 15 inhibits Aβ1-42-induced GSK-3β and tau protein phosphorylation. GSK-3β inhibitor 15 inhibits LPS-induced iNOS expression. GSK-3β inhibitor 15 has neuroprotective effects on Aβ1-42-induced neurotoxicity. GSK-3β inhibitor 15 can be used for research of Alzheimer’s disease (AD).
  • HY-149418
    BChE/HDAC6-IN-2
    		Inhibitor
    BChE/HDAC6-IN-2 (compound 29a) is a dual inhibitor of BChE and HDAC6 with IC50s of 1.8 nM and 71.0 nM, respectively. BChE/HDAC6-IN-2 has prominently neuroprotective effects and reactive oxygen species (ROS) scavenging activity. BChE/HDAC6-IN-2 is also an effective chelator of metal ion (Fe2+ and Cu2+). BChE/HDAC6-IN-2 inhibits phosphorylation of tau, and exhibits moderate immunomodulatory effect.
  • HY-162020
    SB1617
    		Inhibitor
    SB1617 is a neuroinflammation-modulating agent, and has neuroprotective effect by reducing pathogenic tau levels through microglia-mediated anti-inflammatory activity.
  • HY-116753
    (-)Clausenamide
    		Inhibitor 99.92%
    (-)Clausenamide is an active alkaloid isolated from the leaves of Clausena lansium (Lour.) Skeels, and improves cognitive function in both normal physiological and pathological conditions. (-)Clausenamide inhibits β-amyloid (Aβ) toxicity, blocking neurofibrillary tangle formation by inhibiting the phosphorylation of tau protein. (-)Clausenamide exerts a significant neuroprotective activity against Aβ25-35. (-)Clausenamide can be used for researching Alzheimer's disease (AD).
  • HY-168857
    GSK-3β inhibitor 24
    		Inhibitor
    GSK-3β inhibitor 24 (Compound 41) is a potent GSK-3β inhibitor with an IC50 of 0.22 nM. GSK-3β inhibitor 24 increases GSK-3β phosphorylation at Ser9 site dose-dependently. GSK-3β inhibitor 24 inhibits the hyperphosphorylation of tau protein by decreasing the p-tau-Ser396 abundance. GSK-3β inhibitor 24 up-regulates β-catenin and neurogenesis-related markers (GAP43 and MAP-2). GSK-3β inhibitor 24 demonstrates remarkable anti-Alzheimer's disease (AD) effects.
  • HY-161448
    Tau-aggregation-IN-3
    		Inhibitor
    Tau-aggregation-IN-3 (compound 9) a Tau protein aggregation inhibitor (TAI). Tau-aggregation-IN-3 shows activity in cell-based aggregation inhibition experiments (EC50=4.816 μM). Tau-aggregation-IN-3 can be used in Alzheimer's disease research.
  • HY-149233
    hAChE-IN-1
    		Inhibitor
    hAChE-IN-1 (Compound 24) is a potent hAChE inhibitor with an IC50 of 1.09 μM. hAChE-IN-1 inhibits tau-oligomerization with an EC50 of 2.71 μM in cellular tau FRET assay.
  • HY-164341
    TAU-IN-2
    		Inhibitor
    TAU-IN-2 (Example 25) is a TAU inhibitor with an EC50 value of 7.7 nM. TAU-IN-2 can be used in the study of neurodegenerative diseases.
  • HY-120744
    LDN-193665
    		Inhibitor
    LDN-193665 is a Tau kinase inhibitor with tauopathy-modifying activity. LDN-193665 inhibits Tau phosphorylation, improves tauopathy in animal models, reduces Sarkosyl-insoluble Tau, and restores memory. It may be necessary to simultaneously target multiple kinases to effectively inhibit tauopathies.
  • HY-13486
    TAU-IN-1
    		Inhibitor
    TAU-IN-1 (compound 051) is a TAU protein inhibitor with an EC50 value of 325 nM. TAU-IN-1 can be used in the study of neurodegenerative diseases.
  • HY-153427
    Tau protein aggregation-IN-1
    		Inhibitor
    Tau protein aggregation-IN-1 (Compound 0c) is a Tau protein aggregation inhibitor. Tau protein aggregation-IN-1 can be used in the study of protein folding disorders such as Alzheimer's disease, dementia, Parkinson's disease, Huntington's disease and prion-based spongiform encephalopathies.